Because XPO1 regulates both BCL-2 and MCL-1 transport from the nucleus to the cytoplasm for translation [with a chaperon protein Leucine-rich PPR-motif-containing protein (LRPPRC)], SINE compounds/BCL2 inhibitor combination was shown to enhance cell death in in vitro experiments and patient-derived xenograft models in AML. Here, BCL2 is linked to acute myeloid leukemia.